|
|
||||||||
Departments of Molecular and Cellular Physiology and Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0576
| |
ABSTRACT |
|---|
|
|
|---|
Phospholamban (PLB) regulates
Ca2+- adenosinetriphosphatase
activity in cardiac sarcoplasmic reticulum and participates in the regulation of myocardial performance. Animal models with altered levels
of PLB permit in vivo evaluation of the physiological role of PLB. This
study examined left ventricular (LV) performance in intact PLB
heterozygous and homozygous mice under basal and stimulated conditions.
A Millar Mikro-Tip transducer was inserted into the right carotid
artery and advanced into the LV for direct measurement of ventricular
pressure and the first derivative of intraventricular pressure
(dP/dt). Baseline blood pressures
were increased in PLB heterozygotes and even more so in PLB homozygotes compared with wild types (WT), and there were no differences in heart
rate or LV end-diastolic pressure. The increase in pressure was
primarily caused by an increase in systolic pressure. Baseline values
for positive and negative dP/dt were
linearly correlated with PLB levels. In PLB heterozygotes, contractile
response to isoproterenol (Iso) was blunted compared with WT, but
maximum rates of contraction were similar between the two groups.
Contractile performance in PLB homozygous mice, which under baseline
conditions was similar to maximum levels seen in WT, showed a blunted
response to Iso, and maximum rates of contraction were significantly
greater than in either of the other groups, indicating an essential but perhaps not exclusive role for PLB in mediating the inotropic effects
of
-adrenergic agonists. The effects of Iso on negative dP/dt were also blunted in both PLB
heterozygous and PLB homozygous animals. Our results demonstrate that
myocardial function is highly dependent on PLB level and suggest that
the cardiovascular effects of PLB perturbations are largely
uncompensated for in the intact mouse.
left ventricular pressure; first derivative of intraventricular pressure; heart; calcium adenosinetriphosphatase; gene targeting; gene knockout; cardiac contractility
| |
INTRODUCTION |
|---|
|
|
|---|
THE PHOSPHOPROTEIN phospholamban (PLB) is a key
regulator of
Ca2+-adenosinetriphosphatase
(ATPase) in cardiac sarcoplasmic reticulum (3, 5, 6, 14, 15) and has
been shown to contribute to the regulation of myocardial contractility
(4, 7, 10, 11, 16). The role of PLB in the control of myocardial
performance has been investigated recently through the generation of
animal models with targeted ablation of the PLB gene. The resulting
heterozygous and homozygous PLB-mutant mice appear outwardly normal and
express predicted levels of PLB protein (10, 11). Ex vivo studies utilizing isolated cardiac myocytes (16) and isolated, perfused, work-performing hearts (10, 11) indicated that basal contractile parameters were directly correlated with PLB protein levels. In addition, the contractile response to
-adrenergic stimulation was
blunted in PLB heterozygous hearts and myocytes and further attenuated
in those from PLB homozygous animals. Importantly, although the
-adrenergic response was completely abolished in work-performing
hearts from PLB homozygous mice, isolated myocytes from these animals
retained a substantial response to
-adrenergic stimulation (10, 11,
16).
Although these ex vivo studies establish the importance of PLB in
mediating basal and stimulated myocardial performance in isolated
myocytes and hearts, the relative role of this protein in mediating in
vivo contractility is not entirely clear. Neuronal and/or
humoral inputs to the heart, not present in isolated preparations, may
be able to access other cardiac regulatory pathways and influence cardiac function even in the absence of PLB. It is further possible that the PLB knockout mice might develop various compensatory mechanisms that allow them to regulate cardiac performance in the
complete absence of PLB. In fact, previous M-mode echocardiographic studies (4) have indicated that although some indexes of baseline cardiac performance, such as the velocity of circumferential
shortening, were moderately enhanced in PLB knockout mice, other
indexes, such as fractional shortening (a commonly used ejection-phase index of myocardial performance), were unaltered. Furthermore, unlike
the isolated heart preparation, PLB knockout mice retained a
substantial inotropic response to
-adrenergic stimulation as determined by M-mode echocardiography. Thus some of the
echocardiographic findings in the intact mice resembled those obtained
in ex vivo preparations, whereas others were different from the
observations in isolated myocytes and hearts. The present study was
therefore undertaken to quantitatively examine left ventricular (LV)
performance in intact, anesthetized PLB heterozygous and PLB homozygous
mice, using a direct and sensitive method for evaluating isovolumic indexes of myocardial performance. Closed-chest mice were instrumented with a high-fidelity Millar micromanometer for the measurement of LV
pressure (LVP) and first derivative of intraventricular pressure
(dP/dt) under basal and
-stimulated conditions. These studies sought to clarify three
important issues. 1) What is the relative level of contractility in the intact animal under basal conditions, maximally stimulated (10, 11) or partially stimulated (4,
16)? 2) What is the dose-response
relationship to
-adrenergic stimulation in the intact PLB-deficient
animals compared with wild types? 3)
Are there mechanisms independent of PLB that can produce an inotropic
response in the intact PLB knockout mouse?
| |
METHODS |
|---|
|
|
|---|
Mouse colony. PLB homozygous, PLB heterozygous, and wild-type mice were obtained from an established colony generated at the University of Cincinnati as previously described (10). Genotype was determined by polymerase chain reaction analysis of tail biopsies and by Southern blot analysis.
Surgery and experimental protocols. Age-matched mice weighing between 25 and 35 g were allowed free access to food and water up to the time of surgery. Assessment of LV function was performed as previously described (9). Briefly, mice were anesthetized with intraperitoneal injections of 50 µg/g body weight (BW) of ketamine and 100 µg/g BW thiobutabarbital (Inactin, Research Biochemicals International, Natick, MA) and placed on a thermally controlled surgical table. After tracheostomy, the right femoral artery and vein were cannulated with polyethylene tubing (OD 0.3-0.5 mm). The arterial catheter was connected to a COBE CDXIII fixed-dome pressure transducer (COBE Cardiovascular, Arvada, CO) for measurement of arterial blood pressure, and the venous catheter was connected to a syringe pump for the infusion of experimental drugs. The right carotid artery was then cannulated with a high-fidelity, 1.8-F Millar Mikro-Tip transducer (model SPR-612, Millar Instruments, Houston, TX). During continual monitoring of the blood pressure wave, the tip of the transducer was carefully advanced through the ascending aorta and into the LV. When a stable waveform, characteristic of the ventricular pressure profile, was achieved, the transducer was anchored in place using 7-0 silk sutures. After surgery was completed, animals were allowed to stabilize for 30-45 min.
LV measurements.
Cardiovascular responses to increasing doses of isoproterenol (Iso)
administered as a constant infusion (0.01, 0.02, 0.04, 0.08, 0.16, and
0.32 ng · min
1 · g
BW
1) were determined.
Each dose was delivered at a rate of 0.1 µl/g BW for 3 min, and
animals were allowed to recover to baseline for 10-15 min between
doses. After completion of the dose-response protocol, a bolus dose of
propranolol (100 ng/g BW) was administered to evaluate baseline cardiac
function in the absence of endogenous
-adrenergic activity.
Aortic measurements. In a separate protocol, systolic and diastolic pressures in the ascending aorta were determined to evaluate the differences in mean arterial pressure (MAP). Surgery was performed as described, except that the tip of the Millar catheter was positioned just at the entrance of the right carotid artery.
Analytical and statistical procedures.
Pressure signals were recorded using a MacLab 4/s data acquisition
system at a sampling rate of 1,000 samples · s
1 · channel
1.
Average values for MAP, heart rate (HR), systolic and diastolic LVP,
and LV end-diastolic pressure (LVEDP) were determined for 20- to 30-s
periods. Several indexes of ventricular performance were calculated
from the ventricular dP/dt tracing:
maximum and minimum dP/dt
(dP/dtmax,
dP/dtmin),
dP/dt at 40 mmHg of developed pressure
(dP/dt40, an
index that attempts to correct for differences in afterload), and
dP/dtmax divided
by the developed pressure at
dP/dtmax
(dP/dtmax/DP, an
index that attempts to correct for differences in preload).
| |
RESULTS |
|---|
|
|
|---|
Basal cardiac function.
To evaluate cardiac function in the absence of endogenous
-adrenergic activity, animals were treated with the
-adrenergic blocker propranolol. These measurements were performed at the end of
each experiment to avoid interference with the Iso dose-response relationship. Baseline values for whole animal cardiovascular function
are shown in Table 1, and these data
demonstrate that, compared with wild-type animals, myocardial
performance
(dP/dtmax, dP/dt40, and
dP/dtmax/DP) is
increased in the heterozygous and even more so in the homozygous
knockout mice. There were no differences in HR and LVEDP among any of
the three groups of animals. MAP and LV systolic pressure were elevated
in PLB heterozygous animals compared with wild types, and pressures in
the PLB homozygous animals were significantly greater than in both
wild-type and PLB heterozygous animals. This increased blood pressure
in PLB homozygous mice, which has not been reported previously, was
further investigated in a separate series of experiments (see
Ascending aortic pressure
measurements). All three indexes of
myocardial contractility,
dP/dtmax,
dP/dt40, and
dP/dtmax/DP, were
significantly elevated in the PLB heterozygous animals compared with
wild types; they were also elevated in the PLB homozygous animals
compared with both wild-type and PLB heterozygous animals. The index
for myocardial relaxation,
dP/dtmin, was
significantly increased (more negative) in the PLB heterozygous animals
compared with wild types (P < 0.0017) and significantly increased in the PLB homozygous animals
compared with both wild-type (P < 0.0001) and PLB heterozygous animals
(P < 0.0003).
|
|
Responses to
-adrenergic stimulation.
To compare the responsiveness of the three groups of animals to
-adrenergic stimulation, the dose-response relationships for
intravenous infusions of Iso were determined in each group of animals.
As shown in Fig. 2, increasing doses of Iso
resulted in significant increases in HR throughout the dose-response
relationship, and there were no differences among the three groups of
animals at any dose of Iso. Similarly, LVEDP decreased significantly in response to Iso in all three groups of animals, and there were no
differences among the groups at any dose of Iso. Although MAP and LV
systolic pressure were largely stable throughout the dose-response relationship, there were modest but statistically significant responses
to Iso in some groups. MAP decreased slightly in both the PLB
heterozygous (P < 0.002) and PLB
homozygous (P < 0.0001) animals in
response to Iso but remained unchanged in the wild types. In a similar
pattern of response, LV systolic pressure remained unchanged in PLB
heterozygous and PLB homozygous animals, but increased slightly
(P < 0.01) in wild-type animals in
response to Iso.
|
-adrenergic stimulation are illustrated in
Fig. 3, which shows the Iso dose-response
relationships for
dP/dtmax,
dP/dt40, and
dP/dtmax/DP in
the three groups of animals. Similar to the findings in
propranolol-treated animals, the untreated baseline values for
dP/dtmax were
significantly greater in PLB heterozygotes compared with wild types and
greater yet in PLB homozygous animals
(P < 0.0001 for all comparisons). However, when these data are related with those in Table 1, it is
interesting to note that compared with untreated animals, treatment with propranolol caused a significant decrease in myocardial
performance in the wild-type animals (7,181 ± 754 vs. 9,426 ± 539 mmHg/s) but not in the PLB heterozygous and PLB
homozygous animals (13,407 ± 487 vs. 13,039 ± 432 and
18,154 ± 640 vs. 18,372 ± 313 mmHg/s, respectively). In
response to Iso,
dP/dtmax
increased in a dose-dependent manner in all three groups of animals,
but the magnitude of this response was blunted in the PLB heterozygous
animals compared with the wild types, such that the maximum values of
dP/dtmax were not
different from each other. In the PLB homozygous animals, the magnitude
of the Iso response was further blunted compared with PLB
heterozygotes, but the maximum value of
dP/dtmax was actually greater than in the PLB
heterozygous (P < 0.0023) or wild-type (P < 0.046) animals. This pattern of response was also observed for the
other two indexes of myocardial performance, dP/dt40 and dP/dtmax/DP
(Fig. 3). The only difference was that at the highest dose
of Iso, dP/dtmax/DP was greater in the PLB heterozygotes than in the wild types (P < 0.0007) and
greater still in the PLB homozygotes (P < 0.0001 compared
with wild types and P < 0.0014 compared with PLB
heterozygotes).
|
|
Ascending aortic pressure measurements. The differences in blood pressure described in Basal cardiac function contrast with previously reported findings using tail cuff measurements (10). To further evaluate these differences, we examined mean, systolic, and diastolic pressures in wild-type and PLB homozygous mice by placing the Millar transducer in the ascending aorta, at the origin of the carotid artery. We confirmed that MAP was higher in the PLB homozygous mice than in wild types: 114 ± 8 vs. 93.4 ± 4 mmHg (P < 0.05). This difference was largely reflective of an increase in systolic pressure and owed less to an increase in diastolic pressure. Systolic pressure was 107 ± 4 mmHg in the wild-type and 140 ± 10 mmHg in the PLB-deficient animals (P < 0.01), whereas diastolic pressure was 81 ± 4 and 93 ± 8 mmHg (P = 0.225) in the wild-type and PLB homozygous mice, respectively.
| |
DISCUSSION |
|---|
|
|
|---|
The findings of the present study are the first to quantitatively
demonstrate that, in the intact animal, cardiac performance is
critically dependent on the level of PLB gene expression in the murine
myocardium. Furthermore, the present results demonstrate that
1) the cardiovascular effects of PLB
perturbations are, to a large extent, uncompensated for in the intact
mouse and 2) PLB deficiency is
associated with increased MAP, largely owing to an increase in systolic
pressure. These PLB "gene-dosage" effects on blood pressure and
myocardial performance dramatically illustrate the relative role and
importance of PLB in regulating cardiovascular function in the fully
intact animal. PLB deficiency was also associated with a markedly
blunted, but not abolished,
-adrenergic dose-response relationship.
However, because PLB homozygous animals did respond to
-adrenergic
stimulation, albeit slightly, these data suggest that the role of PLB
in mediating the inotropic response to
-stimulation is not
exclusive.
The dependence of MAP on PLB gene expression illustrated in this study is intriguing. It was originally reported that MAP, as assessed by tail-cuff sphygmomanometry (10), was not different in PLB homozygous animals compared with wild types. We report here, in two separate series of experiments (aortic and LV), that MAP measured intra-arterially under anesthesia is significantly increased in PLB-deficient animals. The reason for these different findings is not entirely clear but may be that tail-cuff measurements cannot discern subtle differences in pressure or alternatively that actual differences exist between awake and anesthetized animals. Use of the Millar catheter to measure pressure in the ascending aorta permitted precise determination of systolic and diastolic pressure that would not be possible using a fluid-filled catheter. The resulting data demonstrate that the increased MAP in PLB-deficient mice is largely reflective of an increased systolic pressure, suggesting that the observed hypertension is caused more by a difference in cardiac performance than by a difference in vascular reactivity. However, because PLB is expressed in vascular smooth muscle (8), a vascular component to the observed difference in blood pressure cannot be ruled out. It is interesting to note that, although PLB deficiency was consistently associated with increased blood pressure in both aortic and LV experiments, the actual blood pressure values were substantially higher in the aortic experiments than in the LV experiments, a difference that may be related to the ages of the animals. Mice used in the LV experiments were ~12 wk of age, whereas those in the aortic experiments were ~16 wk of age. This possible age dependence of blood pressure will require further investigation.
Previous studies using the isolated heart preparation (10, 11) showed
that contractile parameters
(dP/dtmax and
time to peak pressure) in PLB homozygous hearts under baseline
conditions were elevated to levels that were not different from the
maximal levels observed with
-adrenergic stimulation in wild-type
hearts. In addition, these earlier studies showed that
-stimulation
of the PLB homozygous hearts with Iso produced no further increments in
contractility. In contrast, studies using M-mode echocardiography reported that ejection-phase indexes of cardiac performance (fractional shortening and velocity of circumferential shortening) in PLB homozygous mice under baseline conditions were either not different from or moderately increased compared with wild-type animals
(suggesting significant compensation in the intact animal) and that
-adrenergic stimulation resulted in increases in cardiac performance
to similar levels in the two groups of animals (4). It is known,
however, that ejection-phase indexes of ventricular function can be
highly dependent on peripheral vascular function (2), which may be altered in PLB homozygous mice as suggested by the blood pressure data
discussed in RESULTS. Thus, based on
the data from these previous studies, it is not clear whether the
effects of PLB deficiency are compensated for in the intact animal or
whether there are PLB-independent mechanisms available to the intact
animal that are able to mediate an inotropic response to
-adrenergic
stimulation. To address these issues, the present study sought to
examine isovolumic indexes of cardiac performance. Values for
dP/dtmax,
dP/dt40, and
dP/dtmax/DP were
greatly enhanced in PLB homozygous animals under baseline conditions,
and the inotropic response to
-stimulation was severely but not
completely blunted. It appears, therefore, that in the intact animal,
changes in myocardial contractility induced by PLB perturbations are
largely uncompensated. That is, presumed neurogenic or hormonal
systemic mechanisms attempting to slow the heart are largely unable to
decrease cardiac contractility in the face of PLB deficiency.
Furthermore, although PLB deficiency dramatically blunted the response
to
-adrenergic stimulation, there seemed to be residual mechanisms
available to the intact animal to further increase contractility. It
may be reasonable to speculate that because the chronotropic effects of
-adrenergic stimulation are fully intact in the PLB-deficient
animal, the increase in cardiac performance may be related to the
treppe phenomenon (1). In this regard, in separate experiments using an
atrial pacing electrode to directly increase HR, we have observed that HR increases within the range observed here have only mild effects on
dP/dt (i.e., <1,000 mmHg/s; data not
shown). Other possible regulatory mechanisms include phosphorylation of
other proteins, such as sarcoplasmic reticulum
Ca2+-ATPase (15), troponin I (7),
ryanodine receptor (18), and phospholemman (13).
Several indexes of myocardial performance, which attempt to correct for differences in loading conditions, were determined in the present study in addition to dP/dtmax. We calculated dP/dt40, an index that attempts to correct for differences in preload (12), and dP/dtmax/DP, which attempts to correct for afterload differences (17). These contractile indexes were largely consistent in their evaluation of myocardial performance in the three groups of mice over the full range of the Iso dose-response relationship, and these data reinforce the hypothesis that PLB-deficient animals retain a preload- and afterload-independent mechanism for increasing myocardial contractility. We also evaluated cardiac relaxation in these experiments and, consistent with previous reports (10, 11), found that dP/dtmin was elevated by ~40% in the PLB heterozygotes and nearly doubled in the PLB homozygous animals compared with wild types under basal conditions.
In summary, the results of the present study demonstrate that both
basal and stimulated myocardial function in the intact animal is highly
dependent on the relative level of PLB. Under basal conditions, cardiac
contractile parameters were significantly elevated in the PLB
heterozygotes and even more so in the PLB homozygotes compared with the
wild types. Furthermore, because these differences in myocardial
performance persisted in the fully intact mouse, the cardiovascular
effects of PLB perturbations appear to be largely uncompensated in
vivo. The dramatically elevated basal contractile performance in the
PLB homozygotes was associated with a blunted response to
-adrenergic stimulation. However, because the response to
-adrenergic agonists was not completely abolished, the
data suggest that the role for PLB in mediating the inotropic effects
of
-agonists is not exclusive.
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by the American Heart Association (AHA), Ohio Affiliate, AHA Project No. SW-95-33-I and National Heart, Lung, and Blood Institute Grants HL-26057, HL-22619, and HL-52318.
| |
FOOTNOTES |
|---|
Address for reprint requests: J. N. Lorenz, Dept. of Molecular and Cellular Physiol., Univ. of Cincinnati, PO Box 670576, Cincinnati, OH 45267-0576.
Received 17 October 1996; accepted in final form 26 August 1997.
| |
REFERENCES |
|---|
|
|
|---|
1.
Furnival, C. M.,
R. J. Linden,
and
H. W. Snow.
Inotropic changes in the left ventricle: the effect of changes in heart rate aortic pressure and end-diastolic pressure.
J. Physiol. (Lond.)
211:
359-87,
1970
2.
Grossman, W.
Evaluation of systolic and diastolic function of the myocardium.
In: Cardiac Catheterization, Angiography, and Intervention, edited by D. S. Baim,
and W. Grossman. Baltimore, MD: Williams and Wilkins, 1996, p. 333-355.
3.
Hicks, M. J.,
M. Shigekawa,
and
A. M. Katz.
Mechanism by which cyclic adenosine 3': 5'-monophosphate-dependent protein kinase stimulates calcium transport in cardiac sarcoplasmic reticulum.
Circ. Res.
44:
384-391,
1979
4.
Hoit, B. D.,
S. F. Khoury,
E. G. Kranias,
N. Ball,
and
R. A. Walsh.
In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency.
Circ. Res.
77:
632-637,
1995
5.
James, P.,
M. Inui,
M. Tada,
M. Chiesi,
and
E. Carafoli.
Nature and site of phospholamban regulation of the Ca2+ pump of sarcoplasmic reticulum.
Nature
342:
90-92,
1989[Medline].
6.
Kranias, E. G.,
F. Mandel,
T. Wang,
and
A. Schwartz.
Mechanism of the stimulation of calcium ion dependent adenosine triphosphatase of cardiac sarcoplasmic reticulum by adenosine 3': 5'-monophosphate dependent protein kinase.
Biochemistry
19:
5434-5439,
1980[Medline].
7.
Kranias, E. G.,
and
R. J. Solaro.
Phosphorylation of troponin I and phospholamban during catecholamine stimulation of rabbit heart.
Nature
298:
182-184,
1982[Medline].
8.
Lalli, J.,
J. M. Harrer,
W. Luo,
E. G. Kranias,
and
R. J. Paul.
Targeted ablation of the phospholamban gene is associated with a marked decrease in sensitivity in aortic smooth muscle.
Circ. Res.
80:
506-513,
1997
9.
Lorenz, J. N,
and
J. Robbins.
Measurement of intraventricular pressure and cardiac performance in the intact closed-chest anesthetized mouse.
Am. J. Physiol.
272 (Heart Circ. Physiol. 41):
H1137-H1146,
1997
10.
Luo, W.,
I. L. Grupp,
J. Harrer,
S. Ponniah,
G. Grupp,
J. J. Duffy,
T. Doetschman,
and
E. G. Kranias.
Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of
-agonist stimulation.
Circ. Res.
75:
401-409,
1994
11.
Luo, W.,
B. M. Wolska,
I. L. Grupp,
J. M. Harrer,
K. Haghighi,
D. G. Feruson,
J. P. Slack,
G. Grupp,
T. Doetschman,
R. J. Solaro,
and
E. Kranias.
Phospholamban gene dosage effects in the mammalian heart.
Circ. Res.
78:
839-847,
1996
12.
Mason, D. T.,
E. Braunwald,
J. W. Covell,
E. H. Sonnenblick,
and
J. Ross.
Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole.
Circulation
44:
47-58,
1971
13.
Presti, C. F.,
L. R. Jones,
and
J. P. Lindemann.
Isoproterenol-induced phosphorylation of a 15-kilodalton sarcolemmal protein in intact myocardium.
J. Biol. Chem.
260:
3860-3867,
1985
14.
Tada, M.
Molecular structure and function of phospholamban in regulating the calcium pump from sarcoplasmic reticulum.
Ann. NY Acad. Sci.
671:
92-102,
1992[Medline].
15.
Toyofuku, T.,
K. Kurzydlowski,
N. Narayanan,
and
D. H. MacLennon.
Identification of Ser38 as the site in cardiac sarcoplasmic reticulum Ca2+-ATPase that is phosphorylated by Ca2+/calmodulin-dependent protein kinase.
J. Biol. Chem.
269:
26492-26496,
1994
16.
Wolska, B. M.,
M. O. Stojanovic,
W. Luo,
E. G. Kranias,
and
R. J. Solaro.
Effect of ablation of phospholamban on dynamics of cardiac myocyte contraction and intracellular Ca2+.
Am. J. Physiol
271 (Cell Physiol. 40):
C391-C397,
1996
17.
Yang, S. S.,
L. G. Bentivoglio,
V. Maranhão,
and
H. Goldberg.
From Cardiac Catheterization Data to Hemodynamic Parameters. Philadelphia, PA: Davis, 1972, p. 157-210.
18.
Yoshida, A.,
M. Takahashi,
T. Imagawa,
M. Shigekawa,
H. Takisawa,
and
T. Nakamura.
Phosphorylation of ryanodine receptors in rat myocytes during
-adrenergic stimulation.
J. Biochem. (Tokyo)
111:
186-190,
1992
This article has been cited by other articles:
![]() |
S. Huke, V. Prasad, M. L. Nieman, K. J. Nattamai, I. L. Grupp, J. N. Lorenz, and M. Periasamy Altered dose response to beta -agonists in SERCA1a-expressing hearts ex vivo and in vivo Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H958 - H965. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Lorenz A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2002; 282(6): R1565 - R1582. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |